<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02560389</url>
  </required_header>
  <id_info>
    <org_study_id>204583</org_study_id>
    <nct_id>NCT02560389</nct_id>
  </id_info>
  <brief_title>Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)</brief_title>
  <official_title>Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate a new use for a medication called levodopa
      (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic
      Stress Disorder (PTSD). L-DOPA is thought to enhance certain cognitive abilities that the
      investigators believe may be affected among women with PTSD. It is hypothesized that L-DOPA
      may enhance fear extinction learning to a conditioned fear stimulus. If this is true, L-DOPA
      may improve outcomes for those undergoing certain types of therapy for PTSD, though that aim
      is beyond the scope of this project. Additionally, the investigators are testing whether an
      individual's genetic profile affects how well L-DOPA works to enhance cognitive abilities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current state-of-the art treatments for posttraumatic stress disorder (PTSD) are lacking in
      efficacy. There are two main evidence-based psychological treatments for PTSD. Prolonged
      Exposure (PE) is a largely-exposure based intervention that has been found efficacious for
      the reduction of PTSD symptoms; however, PE is associated with post-treatment remission rates
      of only ~53-60%. Cognitive Processing Therapy (CPT) is also a widely studied and efficacious
      psychological treatment for PTSD, which focuses both on exposure to the trauma memory as well
      as cognitive therapy techniques. As with PE, post-treatment remission rates for CPT are only
      ~53-60%, thus also indicating need for improvement in overall efficacy and consistency of
      response across individuals.

      There is emerging research demonstrating that dopamine is critical to the consolidation and
      subsequent recall of fear extinction learning. A recent study of healthy adult humans
      demonstrated that oral administration of 150 mg L-DOPA after fear extinction learning led to
      decreased fear responding, even when tested in a new context. Further, this study also found
      that resting-state functional connectivity, measured ~45 minutes after post-extinction
      learning L-DOPA administration, between the ventral tegmental area (VTA) and mPFC was
      correlated with magnitude of medial prefrontal cortex (mPFC) recruitment during recall of the
      fear extinction learning. This latter finding suggests that the mechanism by which L-DOPA
      boosts consolidation of fear extinction learning is through acutely reorganized dopaminergic
      resting-state networks. Indeed, other studies have demonstrated an acute effect of L-DOPA
      administration on resting-state functional connectivity within dopaminergic neural networks.
      Thus, agents that increase dopamine transmission acutely during the post-extinction learning
      consolidation window, and thereby acutely altering organization of dopaminergic neural
      networks, show promise for boosting the consolidation of fear extinction memories and
      decreasing fear responding.

      Genetic variation is a primary contributor to individual differences in baseline dopamine
      neurotransmission. Individuals with specific alleles in genes coding for high baseline
      dopamine demonstrate better performance on tasks probing working memory, cognitive control,
      and social cognition. Genetic variants in baseline dopamine neurotransmission would therefore
      be expected to modulate performance-enhancing effects of L-DOPA, such that individuals with
      low endogenous would be expected to have increased performance upon exogenously increasing
      dopamine neurotransmission; whereas individuals with high endogenous dopamine would be
      expected to have performance deteriorate from exogenously increasing dopamine
      neurotransmission. In support of this hypothesis, a recent study found an interaction between
      L-DOPA administration and endogenous dopamine neurotransmission (as indicated by a polygenic
      score pooled across catechol-O-methyltransferase (COMT), dopamine transporter protein (DAT),
      dopamine D1 receptor (DRD1-3)) on motor learning performance, such that individuals with a
      combination of alleles coding for higher baseline dopamine demonstrated a weaker learning
      benefit from L-DOPA, whereas individuals with a combination of alleles coding for lower
      baseline dopamine demonstrated a stronger learning benefit from L-DOPA. These data
      demonstrate the non-linear relationship between performance and dopamine levels, suggesting
      that any investigation of potential effects of boosting dopamine neurotransmission as a means
      of boosting learning needs to account for baseline dopamine neurotransmission.

      Overall, the proposed project seeks to demonstrate the engagement of post-extinction dopamine
      neurotransmission and downstream acute reorganization of dopaminergic resting-state neural
      networks as a means of increasing consolidation of generic fear extinction learning in adult
      women with PTSD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">May 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Galvanic Skin Response</measure>
    <time_frame>Within 30 days of the MRI</time_frame>
    <description>Differential galvanic skin response will be assessed with respect to the conditioned stimulus versus the control stimulus. The investigators will compare, at an aggregate level, the differential galvanic skin response between the placebo, 100 mg, and 200 mg L-DOPA groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Functional Activation of Amygdala</measure>
    <time_frame>Within 30 days of the MRI</time_frame>
    <description>Amygdala is the part of the brain which controls emotions, survival instincts, and memory. PTSD patients exhibit hyperactivity in the amygdala in response to stimuli.
Differential functional activation of the amygdala will be assessed with respect to the conditioned stimulus versus the control stimulus. The investigators will compare, at an aggregate level, the differential functional activation between the placebo, 100 mg, and 200 mg L-DOPA groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Activation of Anterior Cingulate Cortex</measure>
    <time_frame>Within 30 days of the MRI</time_frame>
    <description>Differential functional activation of the anterior cingulate cortex will be assessed with respect to the conditioned stimulus versus the control stimulus. The investigators will compare, at an aggregate level, the differential functional activation between the placebo, 100 mg, and 200 mg L-DOPA groups.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Stress Disorder, Post Traumatic</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered in pill form once by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg L-DOPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg levodopa administered in pill form once by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg L-DOPA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg levodopa administered in pill form once by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill packaged to resemble levodopa</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa</intervention_name>
    <description>EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
    <arm_group_label>100mg L-DOPA</arm_group_label>
    <arm_group_label>200mg L-DOPA</arm_group_label>
    <other_name>L-DOPA</other_name>
    <other_name>Larodopa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  25-50 years of age

          -  PTSD related to physical or sexual assault

          -  Medically healthy

          -  English speaking

        Exclusion Criteria:

          -  Claustrophobia, or the inability to lie still in a confined space

          -  Major medical disorders (e.g., HIV, cancer)

          -  Magnetic metallic implants (such as screws, pins, shrapnel remnants, aneurysm clips,
             artificial heart valves, inner ear (cochlear) implants, artificial joints, and
             vascular stents)

          -  Electronic or magnetic implants, such as pacemakers

          -  Permanent makeup or tattoos with metallic dyes

          -  Currently pregnant

          -  A self-reported history of loss of consciousness (greater than 10 minutes)

          -  Physical disabilities that prohibit task performance (such as blindness or deafness)

          -  Psychotic disorders (e.g., schizophrenia)

          -  Any other condition that the investigator believes might put the participant at risk
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josh Cisler, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <results_first_submitted>May 7, 2019</results_first_submitted>
  <results_first_submitted_qc>June 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2019</results_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Posttraumatic Stress Disorder</keyword>
  <keyword>functional Magnetic Resonance Imaging</keyword>
  <keyword>Levodopa (L-DOPA)</keyword>
  <keyword>Exposure Therapy</keyword>
  <keyword>Fear Extinction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02560389/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>103 participants enrolled but only 91 started in the study. 12 participants did not start in the study (6 did not show up, 3 were claustrophobic, 1 was too large to fit in MRI scanner and 2 were tested positive for having used cannabis)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo administered in pill form once by mouth
Placebo: Sugar pill packaged to resemble levodopa</description>
        </group>
        <group group_id="P2">
          <title>100mg L-DOPA</title>
          <description>100mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
        </group>
        <group group_id="P3">
          <title>200mg L-DOPA</title>
          <description>200mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Tested positive for illicit substance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo administered in pill form once by mouth
Placebo: Sugar pill packaged to resemble levodopa</description>
        </group>
        <group group_id="B2">
          <title>100mg L-DOPA</title>
          <description>100mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
        </group>
        <group group_id="B3">
          <title>200mg L-DOPA</title>
          <description>200mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.7" spread="9"/>
                    <measurement group_id="B2" value="35.1" spread="9.7"/>
                    <measurement group_id="B3" value="33.9" spread="8.4"/>
                    <measurement group_id="B4" value="34.23" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Galvanic Skin Response</title>
        <description>Differential galvanic skin response will be assessed with respect to the conditioned stimulus versus the control stimulus. The investigators will compare, at an aggregate level, the differential galvanic skin response between the placebo, 100 mg, and 200 mg L-DOPA groups.</description>
        <time_frame>Within 30 days of the MRI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered in pill form once by mouth
Placebo: Sugar pill packaged to resemble levodopa</description>
          </group>
          <group group_id="O2">
            <title>100mg L-DOPA</title>
            <description>100mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
          </group>
          <group group_id="O3">
            <title>200mg L-DOPA</title>
            <description>200mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Galvanic Skin Response</title>
          <description>Differential galvanic skin response will be assessed with respect to the conditioned stimulus versus the control stimulus. The investigators will compare, at an aggregate level, the differential galvanic skin response between the placebo, 100 mg, and 200 mg L-DOPA groups.</description>
          <units>Unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".37" spread="0.05"/>
                    <measurement group_id="O2" value=".29" spread="0.06"/>
                    <measurement group_id="O3" value=".36" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Functional Activation of Amygdala</title>
        <description>Amygdala is the part of the brain which controls emotions, survival instincts, and memory. PTSD patients exhibit hyperactivity in the amygdala in response to stimuli.
Differential functional activation of the amygdala will be assessed with respect to the conditioned stimulus versus the control stimulus. The investigators will compare, at an aggregate level, the differential functional activation between the placebo, 100 mg, and 200 mg L-DOPA groups.</description>
        <time_frame>Within 30 days of the MRI</time_frame>
        <population>fMRI data was excluded for following number of participants due to artifacts caused by excessive head motion during the scan.
Placebo n=4 participants, 100mg L-DOPA n=3 participants, 200mg L-DOPA n=3 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered in pill form once by mouth
Placebo: Sugar pill packaged to resemble levodopa</description>
          </group>
          <group group_id="O2">
            <title>100mg L-DOPA</title>
            <description>100mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
          </group>
          <group group_id="O3">
            <title>200mg L-DOPA</title>
            <description>200mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Functional Activation of Amygdala</title>
          <description>Amygdala is the part of the brain which controls emotions, survival instincts, and memory. PTSD patients exhibit hyperactivity in the amygdala in response to stimuli.
Differential functional activation of the amygdala will be assessed with respect to the conditioned stimulus versus the control stimulus. The investigators will compare, at an aggregate level, the differential functional activation between the placebo, 100 mg, and 200 mg L-DOPA groups.</description>
          <population>fMRI data was excluded for following number of participants due to artifacts caused by excessive head motion during the scan.
Placebo n=4 participants, 100mg L-DOPA n=3 participants, 200mg L-DOPA n=3 participants</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.05"/>
                    <measurement group_id="O2" value="-0.06" spread="0.04"/>
                    <measurement group_id="O3" value="-0.05" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Activation of Anterior Cingulate Cortex</title>
        <description>Differential functional activation of the anterior cingulate cortex will be assessed with respect to the conditioned stimulus versus the control stimulus. The investigators will compare, at an aggregate level, the differential functional activation between the placebo, 100 mg, and 200 mg L-DOPA groups.</description>
        <time_frame>Within 30 days of the MRI</time_frame>
        <population>Data was excluded for following number of participants due to artifacts caused by excessive head motion during the scan.
Placebo n=4 participants, 100mg L-DOPA n=3 participants, 200mg L-DOPA n=3 participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo administered in pill form once by mouth
Placebo: Sugar pill packaged to resemble levodopa</description>
          </group>
          <group group_id="O2">
            <title>100mg L-DOPA</title>
            <description>100mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
          </group>
          <group group_id="O3">
            <title>200mg L-DOPA</title>
            <description>200mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Activation of Anterior Cingulate Cortex</title>
          <description>Differential functional activation of the anterior cingulate cortex will be assessed with respect to the conditioned stimulus versus the control stimulus. The investigators will compare, at an aggregate level, the differential functional activation between the placebo, 100 mg, and 200 mg L-DOPA groups.</description>
          <population>Data was excluded for following number of participants due to artifacts caused by excessive head motion during the scan.
Placebo n=4 participants, 100mg L-DOPA n=3 participants, 200mg L-DOPA n=3 participants</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.07"/>
                    <measurement group_id="O2" value="0.09" spread="0.04"/>
                    <measurement group_id="O3" value="0.07" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <desc>Non-systematic</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo administered in pill form once by mouth
Placebo: Sugar pill packaged to resemble levodopa</description>
        </group>
        <group group_id="E2">
          <title>100mg L-DOPA</title>
          <description>100mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
        </group>
        <group group_id="E3">
          <title>200mg L-DOPA</title>
          <description>200mg levodopa administered in pill form once by mouth
Levodopa: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Josh Cisler</name_or_title>
      <organization>University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Madison</organization>
      <phone>608-263-6100</phone>
      <email>jcisler2@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

